Rep. James Clyburn says the Trump Administration may have deliberately tried to "conceal and destroy evidence that senior political appointees interfered" with the CDC's coronavirus response.
NPR's Ari Shapiro talks with Health and Human Services Secretary Alex Azar about the Food and Drug Administration allowing the use of convalescent plasma to treat COVID-19.
The first suspected U.S. case of novel coronavirus infection through "community spread" was left undiagnosed for days, hospital officials said, because the case didn't fit the CDC's criteria.
Speaking from a retirement community in Florida, the president gave seniors a pep talk about what he wants to do for Medicare, contrasting it with plans of his Democratic rivals.
The administration called on other nations to oppose efforts to promote access to abortion. Dozens of other countries signed a competing statement supporting sexual and reproductive health care.
A federal lawsuit seeks to block the Food and Drug Administration from taking enforcement actions against a European doctor or her U.S.-based patients for prescribing or buying abortion pills online.
Health and Human Services outlined two pathways for importing the drugs to the U.S., a plan Secretary Alex Azar says is intended to "lower prices and reduce out of pocket costs for American patients."
A broad executive order issued Monday is supposed to help consumers get better estimates of health care costs. But whether it will be a game changer depends on the details, say health care analysts.
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better.
New short-term insurance policies will likely be cheaper than Affordable Care Act plans. But those lower prices mean they won't pay for as much health care.
At the same time, HHS Secretary Alex Azar criticized the deadlines as "artificial" and said that they prevent the government "from completing our standard or even a truncated vetting process."
After criticism that the administration's blueprint for drug prices was vague, the secretary of health and human services zeroed in on actions that he said need only his signature.
